M. Mostafa, AlaaPan, ZiyanYu, Ming-LungÖrmeci, NecatiFouad, YasserEslam, Mohammed2025-08-212025-08-212025M. Mostafa, A., Pan, Z., Yu, M. L., Örmeci, N., Fouad, Y., & Eslam, M. (2025). MAFLD: A comprehensive review of the link between metabolic dysfunction and cardiovascular risk. Hepatic Medicine: Evidence and Research, 17, pp. 75-90. https://doi.org/10.2147/HMER.S5064021179-1535https://doi.org/10.2147/HMER.S506402https://hdl.handle.net/20.500.13055/1084Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over 30% of the global population. It is a multisystem condition with a strong association with cardiovascular disease (CVD), the leading cause of mortality worldwide. Key shared mechanisms, including insulin resistance, systemic inflammation, oxidative stress, and genetic predisposition, couple MAFLD with increased risks of coronary artery disease, ischemic heart disease, and heart failure. Early detection via non-invasive imaging and biomarkers is crucial for effective risk stratification. Management strategies emphasize lifestyle modifications and the development of targeted pharmacotherapies addressing metabolic and inflammatory pathways. Understanding the interconnected pathogenic mechanisms facilitates personalized interventions to reduce morbidity and improve long-term outcomes. A multidisciplinary approach remains essential to prevent and manage the cardiovascular implications of MAFLD.eninfo:eu-repo/semantics/openAccessFatty LiverCardiometabolic RiskMetabolic DysfunctionPharmacotherapyReview Article10.2147/HMER.S506402177590Q3WOS:001552539100001PMID: 40860752